Is @entity1499 an acceptable treatment in the management of XXXX ?

@entity1 @entity6 @entity10516 @entity228 @entity134 @entity1500 @entity230 @entity1499
PURPOSE: The treatment of choice for @entity10516 ( @entity10516 ) has not yet been established. There are limited data on the use of @entity1499 ( @entity1500 ) in the treatment of @entity10516 . Herein, we investigated the role of @entity1500 in the treatment of @entity10516 @entity1 . METHODS: We present four new cases of @entity10516 treated with @entity1500 and a review of the English language literature concerning the use of @entity1500 in the treatment of @entity10516 . RESULTS: We prospectively investigated the clinicopathological features of four female @entity1 (aged 28-37 years) who were multiparous and had used oral contraceptives. The @entity1 were administered 7.5-15 mg @entity1500 over 2-6 months. No recurrence was detected during the follow-up period of 4-8 months. In five published studies on @entity1500 use in @entity10516 , data were available for 12 @entity1 aged 21-40 years. In nine @entity1 , treatment was changed to @entity1500 because of a lack of response to @entity230 , recurrence or @entity134 -induced @entity6 . @entity230 were used in combination with @entity1500 as an initial treatment choice in three @entity1 . Satisfactory results were achieved in ten @entity1 treated with @entity1500 , and only two demonstrated recurrence despite the treatment and underwent mastectomy. CONCLUSION: @entity1500 in the present cases of @entity10516 was effective, prevented complications and limited @entity228 side effects.
